SNYR: Synergy CHC Company Value to Net Income

Corporate emblem and logo of Synergy CHC (SNYR)

The market valuation of Synergy CHC Corp (SNYR) demonstrates a current P/E ratio of -0.10, which correlates with a slowdown in profit growth due to rising raw material and shipping costs. Synergy CHC Corp is expanding digital commerce and online promotion of wellness products to strengthen its market position. Business protection is ensured by strict cosmetics production standards and exclusive access to retail outlets through recognizable trademarks.

SNYR Synergy CHC Corp.: Price to Earnings Ratio in the range 04/02/2025 - 10/03/2026

Comprehensive metric breakdowns and analytics for Synergy CHC Corp. (SNYR)

- price and consensus price forecast:
Stock Price Synergy CHC Corporation|SNYR - Consensus Target
- market capitalization information:
Market Value Synergy CHC Corp.|SNYR - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Synergy CHC|SNYR - Company Net Assets|Market Cap to Book Value Multiple synergychc.com|SNYR - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Synergy CHC Corp|SNYR - Long-Term Debt to Capital|Current Liabilities to Capital Synergy CHC Corporation|SNYR - Company Debts|Debt to Net Assets Ratio Synergy CHC Corp.|SNYR - Company Long-Term Debt|Short-Term Debt Volume Synergy CHC|Immediate Liquidity synergychc.com
- business earnings and investment ratios data:
SNYR - Company Net Income|Net Profit Forecast Synergy CHC Corp|SNYR - P/E Multiple|Projected Price to Earnings Ratio Synergy CHC Corporation|SNYR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Synergy CHC Corp.|SNYR - Operating profit EBITDA|Net earnings per share for the trailing year Synergy CHC|SNYR - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months synergychc.com|SNYR - Net earnings per share growth this year
Comprehensive company analysis:synergychc.com - SNYR
Flagship merchandise of Synergy CHC

The P/E ratio determines the payback period of a business's market value through net profit, reflecting the balance between objective returns and investor expectations. An analysis of the 12-month trailing (TTM) P/E for Synergy CHC Corp. (SNYR) allows for an assessment of the extent to which the market is willing to pay a premium for the scaling efficiency of niche wellness brands and the precision of digital consumer behavior analytics.

Analysis of competing companies

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|Business Payback Period ARS Pharmaceuticals Inc (SPRY)|TBPH: Price to Earnings Ratio|Market Cap to Earnings Aquestive Corp|scpharmaceuticals.com (SCPH) - Price to Earnings Ratio|Price to Earnings Multiple TECX|TNXP (Tonix Pharmaceuticals Holding Corp.) - P/E Multiple|Market Cap to Earnings SXT China SXTC|Price to Earnings Ratio Eupraxia Pharmaceuticals (EPRX)|BHST (BioHarvest Sciences Inc) - Company Value to Net Income|P/E Multiple EXOZ (eXoZymes Inc)|Market Cap to Net Income Ratio Oramed|ENTX: Price to Earnings Ratio|Market Cap to Earnings MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - Price to Earnings Ratio|Cumberland Corp - Company Value to Net Income|QNTM (Quantum BioPharma Ltd) - P/E Multiple|Price to Earnings Ratio fibrogen.com (FGEN)|P/E Multiple TELO|RANI (ranitherapeutics.com) - Company Value to Net Income|P/E Multiple RLYB (Rallybio)|LEXX - Price to Earnings Ratio|PULM: Price to Earnings Ratio|Company Value to Net Income PTHL (Pheton Holdings Ltd)|APM: P/E Multiple|Price to Earnings Ratio Lyra Therapeutics Inc.|Price to Earnings Ratio Impact BioMedical|Market Cap to Earnings TNF Pharma TNFA|Price to Earnings Ratio cbdMD, Inc. (YCBD)|PRFX (painreform.com) - Company Value to Net Income|Price to Earnings Ratio Altamira Therapeutics Ltd. CYTO|LIPO (Lipella Pharmaceuticals Inc) - Market Cap to Net Income|OPTN - Price to Earnings Ratio|Business Payback Period Pieris Pharma PIRS|Procaps Group S.A. (PROC) - Price to Earnings Ratio|Price to Earnings Multiple PTPI|Price to Earnings Ratio QLI|Market Cap to Earnings Acelyrin Inc. SLRN|Price to Earnings Ratio TFF Pharma (TFFP)